Sugi Predict

Sugi Predict / Compounds / SCHEMBL405696

SCHEMBL405696

SCHEMBL405696

Nc1c(F)cc(Cl)cc1I

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.48
▸ CA2 P00918 5/20 0.48
▸ CA9 Q16790 5/20 0.48
▸ CA3 P07451 1/20 0.48
▸ TP53 P04637 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ TSHR P16473 1/20 0.32
▸ NOS3 P29474 1/20 0.32
▸ NOS1 P29475 1/20 0.32
▸ NOS2 P35228 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11129317 0.82 CYP3A4 (0.45) CA1CA2CA9CA3TP53
SCHEMBL2140713 0.82 CYP3A4 (0.45) CA1CA2CA9CA3TP53
Hydrochloric Acid SCHEMBL2137491 0.79 CYP3A4 (0.43) CA1CA2CA9CA3TP53
SCHEMBL14880913 0.75 CA1 (0.52) CA1CA2CA9CA3
SCHEMBL17650186 0.75 CA1 (0.52) CA1CA2CA9CA3TP53
SCHEMBL405700 0.75 CYP3A4 (0.40) CA1CA2CA9TP53CYP3A4
SCHEMBL2766389 0.75 CA1 (0.52) CA1CA2CA9TP53CYP3A4
SCHEMBL4704594 0.75 CYP3A4 (0.40) CA1CA2CA9TP53CYP3A4
SCHEMBL31213266 0.75 CYP3A4 (0.40) CA1CA2CA9TP53CYP3A4
SCHEMBL28085542 0.75 TSHR (0.35) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111892553-A Method for synthesizing ammonium acetate mediated benzothiazole compound 衡阳师范学院 2020-11-06 — — CN claimed
EP-4747261-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS Accutar Biotechnology Inc. (US) 2026-05-27 — — EP disclosed
US-12338248-B2 Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors ACCUTAR BIOTECHNOLOGY INC. (US) 2025-06-24 — — US disclosed
EP-4562000-A1 AMINOHETEROARYL KINASE INHIBITORS Allorion Therapeutics Inc (US) 2025-06-04 — — EP disclosed
CN-119630652-A Amino heteroaryl kinase inhibitors 安锐生物医药公司 2025-03-14 — — CN disclosed
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors ACCUTAR BIOTECHNOLOGY INC. 2025-03-13 — — US disclosed
WO-2025024388-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2025-01-30 — — WO disclosed
US-12018033-B2 Inhibitors of protein arginine deiminases FORWARD THERAPEUTICS, INC. (US) 2024-06-25 — — US disclosed
WO-2024022487-A1 AMINOHETEROARYL KINASE INHIBITORS Allorion Therapeutics Inc (US) 2024-02-01 — — WO disclosed
US-20230151018-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 — — US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 — — US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 — — US disclosed
US-7473786-B1 Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts UNIVERSITY OF MASSACHUSETTS (US) 2009-01-06 — — US disclosed
EP-1981854-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS Brystol-Myers Squibb Company (US) 2008-10-22 — — EP disclosed
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB CO. 2008-07-03 — — US disclosed
CN-101151245-A Indan-amide derivatives with glycogen phosphorylase inhibitory activity ASTRAZENECA AB (SE) 2008-03-26 — — CN disclosed
EP-1848693-A1 INDAN-AMIDE DERIVATIVES WITH GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-10-31 — — EP disclosed
WO-2007070826-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-06-21 — — WO disclosed
WO-2006082400-A1 INDAN-AMIDE DERIVATIVES WITH GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 CA1 2929/4885CA2 2544/4885CA9 1928/4885
US-12338248-B2 Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors CDK6, CDK2, CDK8 CA1 4670/4885CA2 4287/4885CA9 4467/4885
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors CDK6, CDK2, CDK8 CA1 4670/4885CA2 4287/4885CA9 4467/4885
US-20230151018-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES PADI2, PADI1, PADI4 CA1 2686/4885CA2 2271/4885CA9 3854/4885
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity PYGL, PYGM, GYS1 CA1 2982/4885CA2 647/4885CA9 371/4885
US-12018033-B2 Inhibitors of protein arginine deiminases PADI2, PADI1, PADI4 CA1 2783/4885CA2 2710/4885CA9 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.